Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Latent Tuberculosis: full-pipeline trial registry
3 of 6 indexed Latent Tuberculosis trials are currently recruiting.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Latent Tuberculosis: 6 US clinical trials tracked, 3 recruiting.
Latent Tuberculosis is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 2 of these trials.
Enrollment posture brief
Registry condition latent-tuberculosis
OPEN 3 | RECR 50% | LATE 1 | EARLY 1 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Latent Tuberculosis lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Latent Tuberculosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Latent Tuberculosis is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Latent Tuberculosis research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Latent Tuberculosis enrolment sits around 399 participants.
Median target enrolment is 399 among the 6 trials that report a genuine target (sentinel values excluded). 1 of those (16.7%) plan for fewer than 100 participants.
-
Latent Tuberculosis splits between interventional and observational designs.
4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
Centers for Disease Control and Prevention
NCT03474029
Economic Incentives and vDOT for Latent Tuberculosis Infection
Johns Hopkins University
NCT05022862
Training Protocol on the Natural History of Tuberculosis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01212003
Brief Educational Video for Patients Prescribed LTBI Treatment
Kaiser Permanente
NCT05412212
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
Rutgers, The State University of New Jersey
NCT05411744
Immune Response to Mycobacterium Tuberculosis Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00257907
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Latent Tuberculosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Latent Tuberculosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Latent Tuberculosis page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Latent Tuberculosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Latent Tuberculosis trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Latent Tuberculosis condition card totals 6 registered trials; most-linked intervention 1 month Rifapentine, Isoniazid and Vitamin B6; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.